Biopharma

PhoreMost, the cutting-edge UK biopharmaceutical enterprise specializing in innovative drug development, has successfully closed an impressive £33 million Series B funding round. This latest round, which saw significant oversubscription, underscores the growing confidence in PhoreMost’s pioneering approach to addressing previously untargetable disease mechanisms. Central to PhoreMost’s strategy is their revolutionary SITESEEKER platform. This technology excels…

Lario Therapeutics, a pioneering biopharmaceutical firm dedicated to advancing precision medicines for epileptic and neurological disorders, has been awarded a substantial $6 million USD grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This funding is earmarked to propel Lario’s preclinical research into CaV2.3 calcium channel inhibitors, heralded as a novel approach to…